CONTENTS
· Invitation
· Faculty
· Scientific Agenda
· Continuing
  Medical Education
· Who Should Attend?
· Objectives
· Abstracts
· Registration
· General Information
· Hotel
  Accommodations
· Organizer

Dear Colleague,

It is our pleasure to invite you to join us at Lymphoma & Myeloma 2008: An International Congress on Hematologic Malignancies. This fall’s congress, October 16-18, 2008 at the Waldorf=Astoria in New York, New York, promises to be our most exciting and interactive meeting yet!

Since its inception in 2000, this congress has grown to nearly 800 attendees and has become the premier forum for discussion on the latest advances in lymphoma and myeloma. Using a dynamic approach, featuring clinical controversies, debates, and examinations of current treatment regimens, attendees will receive a thorough understanding of the evolution of thought and therapy of lymphoma and myeloma, as well as any significant developments which may lead to improved results.
Guided by the expertise of the leaders in the fields of molecular biology, pathology, immunology, and translational and clinical research, this congress will provide for a stimulating and interactive forum for attendees from all relevant medical specialties.

Allowing attendees the benefit of visiting New York City during one of the most beautiful times of year, this congress will be the perfect chance for you to get away and enjoy a weekend of learning in the capital city of the world.

We cordially welcome you to our fair city and promise to reward you with an exciting, informative congress!

Sincerely,
Morton Coleman, MD, Chair
John P. Leonard, MD, Co-Chair, Lymphoma Session
Ruben Niesvizky, MD, Co-Chair, Myeloma Session
Richard R. Furman, MD, Co-Chair, Leukemia Session

Lauren E. Abrey, MD
Memorial Sloan-Kettering
Cancer Center
New York, New York

Kenneth C. Anderson, MD, MA
Dana-Farber Cancer Institute
Boston, Massachusetts

Bart Barlogie, MD, PhD
University of Arkansas Medical Center
Little Rock, Arkansas

James R. Berenson, MD
Institute for Myeloma and Bone
Cancer Research
West Hollywood, California

P. Leif Bergsagel, MD, FRCP
Mayo Clinic
Scottsdale, Arizona

Joseph R. Bertino, MD
The Cancer Institute of
New Jersey University
New Brunswick, New Jersey

Franco Cavalli, MD
Oncology Institute of Southern Switzerland
Bellinzona, Switzerland

Amy Chadburn, MD
Center for Lymphoma and Myeloma
Weill Cornell Medical College
New York, New York

Ajai Chari, MD
Columbia University
New York, New York

Selina Chen-Kiang, PhD
Center for Lymphoma and Myeloma
Weill Cornell Medical College
New York, New York

Bruce D. Cheson, MD
Georgetown University Hospital
Washington, District of Columbia

Morton Coleman, MD (Chair)
Center for Lymphoma and Myeloma
Weill Cornell Medical College
The New York Presbyterian Hospital
New York, New York

Rebecca Elstrom, MD
Center for Lymphoma and Myeloma
Weill Cornell Medical College
New York, New York

Scott Ely, MD
Center for Lymphoma and Myeloma
Weill Cornell Medical College
New York, New York

Stephen J. Forman, MD
City of Hope
Duarte, California

Jonathan Friedberg, MD
James P. Wilmot Cancer Center
Rochester, New York

Richard R. Furman, MD (Co-Chair)
Center for Lymphoma and Myeloma
Weill Cornell Medical College
The New York Presbyterian Hospital
New York, New York

Varsha Gandhi, PhD
University of Texas MD
Anderson Cancer Center
Houston, Texas

Irene M. Ghobrial, MD
Mayo Clinic
Rochester, Minnesota

Sergio Giralt, MD
The University of Texas MD
Anderson Cancer Center
Houston, Texas

Jean-Luc Harousseau, MD
University Hospital Hotel-Dieu
Nantes Cedex, France

Neil E. Kay, MD
Mayo Clinic
Rochester, Minnesota

John P. Leonard, MD (Co-Chair)
Center for Lymphoma and Myeloma
Weill Cornell Medical College
The New York Presbyterian Hospital
New York, New York

Brian K. Link, MD
Holden Comprehensive
Cancer Center
Iowa City, Iowa

Isidore Lossos, MD
Sylvester Comprehensive
Cancer Center
Miami, Florida

Cynthia M. Magro, MD
Center for Lymphoma and Myeloma
Weill Cornell Medical College
New York, New York

Tomer Mark, MD
Center for Lymphoma and Myeloma
Weill Cornell Medical College
New York, New York

Ari M. Melnick, MD
Albert Einstein College of Medicine
Bronx, New York

Gareth J. Morgan, MD
The Royal Marsden Hospital
Sutton, United Kingdom

Ruben Niesvizky, MD (Co-Chair)
Center for Lymphoma and Myeloma
Weill Cornell Medical College
The New York Presbyterian Hospital
New York, New York

Roger Pearse, MD
Center for Lymphoma and Myeloma
Weill Cornell Medical College
New York, New York

Kanti Rai, MD
Long Island Jewish Medical Center
New Hyde Park, New York

Jia Ruan, MD, PhD
Center for Lymphoma and Myeloma
Weill Cornell Medical College
New York, New York

Thursday, October 16, 2008

General Session
8:00 am
Welcome and introduction
Morton Coleman, MD

Myeloma Section
8:05 am
Introduction
Ruben Niesvizky, MD

Session I: Molecular biology of myeloma
Chair: Ajai Chari, MD

8:10 am
SNPs in MM: Lessons from MRC trials
Gareth J. Morgan, MD

8:30 am
Cell cycle dysregulation in myeloma: Basic science perspective
Selina Chen-Kiang, PhD

8:50 am
Genomics and the control of cell cycle
P. Leif Bergsagel, MD, FRCP

9:10 am
Panel discussion

9:20 am
Break

Session II: Towards a risk adapted approach
Chair: Scott Ely, MD

9:40 am
Applying proteomics, genomics and cytogenetics to molecular prognostic models
Speaker invited

10:00 am
Evolving staging classifications and response criteria
Speaker invited

10:20 am
What technique is best for determining MRD? And is it necessary?
Scott Ely, MD

10:35 am
Panel discussion

Session III: Treatment I
Chair: Tomer Mark, MD

10:45 am
Initial Therapy: Case presentation with audience participation
Tomer Mark, MD

Friday, October 17, 2008

General Session
8:00 am
Welcome and introduction
Morton Coleman, MD

Session VI: Waldenstrom’sMacroglobulinemia
Chair: Richard R. Furman, MD

8:10 am
Biology and treatment of WM
Irene M. Ghobrial, MD

Session VII: CLL I

Session VIII: CLL II

10:10 am
Targeted therapies in CLL
Richard R. Furman, MD

11:15 am
Luncheon symposium supported by Celgene
Lymphoma Section

Session X: Aggressive lymphomas and Hodgkin’s disease

2:50 pm
Update in the management of DLBCL
Speaker invited

Saturday, October 18, 2008

General Session

8:00 am
Welcome and introduction
Morton Coleman, MD

Session XI: Indolent and mantlecell lymphoma
Chair: Joseph R. Bertino, MD

Session XII: The Best: Highlights from Lugano and Submitted Abstracts
Chair: Morton Coleman, MD

11:10 am
Highlights from the 10th International Conference onMalignant Lymphoma (ICML) in Lugano, Switzerland
Franco Cavalli, MD

11:40 am
Questions & answers

11:50 am
Oral abstract presentation

12:00 pm
Luncheon symposium

Session XIII: Lymphoma & myeloma agents in early development

2:00 pm
Novel agents in CLL
Neil Kay, MD

2:30 pm
Topic to be determined
Speaker to be determined

3:00 pm
Folate antagonists
Joseph R. Bertino, MD

3:15 pm
Bcl-2 inhibitors
Speaker invited

3:30 pm
Syk inhibition
Jonathan Friedberg, MD

3:45 pm
Selective cyclin-dependent kinase inhibitors
Selina Chen-Kiang, PhD

4:00 pm
Anti-angiogenic therapies
Jia Ruan, MD, PhD

4:15 pm
Purine nucleoside phosphorylase inhibitors
Richard R. Furman, MD

4:30 pm
Adjourn

Imedex^®, LLC is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Imedex, LLC designates this educational activity for a maximum 17.0 of AMA PRA Category 1 Credits^TM. Physicians should only claim credit commensurate with the extent of their participation in the activity.

This educational activity is specifically designed for hematologists, oncologists, internists and other physicians, physicians-in-training, and healthcare professionals (nurses, pharmacists) involved in and/or interested in lymphoma, myeloma and related plasma cell disorders and their management.

After attending this educational activity, participants should be able to:

• Use a risk-adapted approach to assimilate current and emerging therapies in achieving complete responses in multiple myeloma
• Review the current role of transplant in myeloma with the advent of successful novel therapies
• Describe the strengths and weaknesses of bisphosphonate therapy in myeloma
• Discuss the chemistry of nucleoside analogs and its relevance to frontline therapy in CLL
• Incorporate targeted therapies and transplantation for improved patient response in CLL
• Discuss the function of PET in Hodgkin’s and non-Hodgkin’s lymphoma
• Review the approach to primary CNS lymphoma and early stage Hodgkin’s
• Employ new strategies and agents for treatment of indolent lymphoma
• Discuss the effectiveness of radioimmunotherapies with monoclonal antibodies to treat patients with relapsed/refractory NHL
• Discuss the most important highlights from the 10th International Conference on Malignant Lymphoma (ICML) in Lugano, Switzerland
• Evaluate lymphoma and myeloma agents in early clinical development for potential to improve upon current therapeutic outcome(s)

New this year! Participants interested in presenting data should submit abstracts online by Friday, July 18, 2008. Abstracts are subject to acceptance by the Scientific Committee. Once accepted, abstracts will be published in the final Summary Book and scheduled for oral or poster presentation.

Acceptance notifications and guidelines for poster presentation will be sent on Friday, August 29, 2008. Authors of accepted abstracts who have not registered will have until Thursday, October 2, 2008 to do so
at the rate of $395.00. After this date, abstracts without registered presenters will be disregarded. Submit your abstract here.

Submission Deadline: Friday, July 18, 2008

Submission Instructions can be found here

Abstract Guidelines

• Follow the online instructions
• Abstracts must be written in English
• Accepted format: Word document format, 9 point Arial font, 500 word count limit
• Use a concise title
• List affiliations of author(s) as briefly as possible, with city, state
  and country
• Place an asterisk (*) before the name of the presenting author
• Use standard and well-accepted abbreviations
• When using references, use standard and well-accepted formats
• Abstract content should be single-spaced, typed in lower case
  and contain:
  • Purpose of the study
  • Summarized description of the project
  • Results and conclusions

Click here to register for this program

PHYSICIAN REGISTRATION FEES
Discounted (Physicians) . . . . . . . . $395
If payment received by August 14, 2008

Regular (Physicians) . . . . . . . . . . .$495
If payment received by October 9, 2008

Full/Onsite (Physicians) . . . . . . . . $595
To register after October 9, 2008

Nurses/Residents/Students*. . . . . . $99
*proof of eligibility must accompany registration

PHARMACIST* REGISTRATION FEES
Discounted . . . . . . . . . . . . . . . . $295
If payment received by August 14, 2008

Regular . . . . . . . . . . . . . . . . . . $345
If payment received by October 9, 2008

Full/Onsite * . . . . . . . . . . . . . . . $395
To register after October 9, 2008

*proof of eligibility must accompany registration

To register: You may register online by Thursday, October 9, 2008 or by calling Imedex at +1 (678) 242 0906. Registration confirmations will be issued before the meeting.

To qualify for special registration fees, registration and full payment must be received by Imedex by the dates specified.

Payment: To register, registration and payment must be received no later than Thursday, October 9, 2008. Please register onsite after this date. Contact Imedex at +1 (678) 242 0906 or visit our website at www.imedex.com to ensure the course is being held as scheduled and to confirm that the meeting is not full. Registration fees must be remitted by credit card or check. Checks should be payable to Imedex. An attendee is not registered until full payment is received.

Registration Fee Inclusions: Registration fees include admittance to all scientific sessions, conference materials, processing of certificates of attendance or continuing medical education, and all event functions as specified in the program.

Cancellation: For registration fees to be refunded, written notice of cancellation must be received at Imedex no later than Thursday, October 9, 2008. The amount of registration fees remitted, minus a $75 administrative charge, will be refunded after the conference. Substitutions are accepted with written notification. No refunds will be made if notice is received after October 9, 2008.

Imedex does not accept responsibility for covering travel, accommodation or any other costs incurred by registrants in the rare event that this meeting should be canceled for any reason. Every effort will be made to give reasonable notice in the event of cancellation. The event agenda is subject to change without notice.

Congress Location and Registration:
The Waldorf=Astoria
301 Park Avenue
New York, New York 10022
Tel.: +1 (212) 355 3000
Fax: +1 (212) 872 7272

The Registration and Information Desk will be staffed:
Thursday, October 16, 2008: 7:00 am – 4:30 pm
Friday, October 17, 2008: 7:30 am – 4:30 pm
Saturday, October 18, 2008: 7:30 am – 4:30 pm

Discounted Airfares
The Congress official agency, Williamsburg Travel Management can assist in making your arrangements. Contact Judi Tarpley, CMP by telephone: +1 (770) 261-8613, toll free: + 1 888-232-9394 or by email judit@willtrav.com

The Waldorf=Astoria
301 Park Avenue
New York, New York 10022
Tel.: +1 (212) 355 3000
Fax: +1 (212) 872 7272
Reservation: (877) 476 8792

As one of the first “grand hotels” to combine luxurious elegance with a myriad of amenities and services, the Waldorf=Astoria has been world renowned for over a century. With a reputation for unparalleled hospitality and service, the Art Deco landmark beckons New Yorkers and visitors alike. Since 1893, The Waldorf=Astoria has epitomized the quintessential luxury hotel experience. Each spacious, individually decorated guest room and suite offers a rewarding union of timeless elegance and up-to-the-moment convenience, luxurious comfort and classic sophistication. The legendary shops of Fifth and Madison Avenues are only minutes away, as are numerous art galleries and specialty shops. The hotel
itself is home to some of the world’s most luxurious boutiques.

For the convenience of attendees, a limited number of rooms have been reserved until September 22, 2008 at a discounted rate of $389 single/double occupancy, plus tax, currently at 13.38% and a $3.50 per night occupancy tax. This rate is not guaranteed outside the conference dates or after September 22, 2008.

To reserve your room please contact the Waldorf=Astoria reservations department at (877) 476 8792 or visit the hotel’s website at www.waldorf.com. To receive the group rate, callers must identify themselves as being with the Lymphoma & Myeloma 2008 group. Internet users must enter the Group/Convention Code: LYA. Reservation requests received after September 22, 2008 may not be guaranteed the group rate.

          4325 Alexander Drive
          Alpharetta, GA 30022-3740 USA
          Tel.: +1 (770) 751 7332
          Fax: +1 (770) 751 7334
          Email: meetings@imedex.com
          Web: www.imedex.com